Suzhou Basecare Medical Corp. Ltd. Class H (HK:2170)
:2170
Top Page
Suzhou Basecare Medical Corp. Ltd. Class H
(2170)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$2.00
▲(1.52% Upside)
Action:ReiteratedDate:11/22/25
The overall stock score of 44 reflects significant challenges in financial performance, technical analysis, and valuation. The company's strong revenue growth is overshadowed by high operating costs and leverage risks, while bearish technical indicators and a negative P/E ratio further weigh down the score. Improvement in operational efficiency and financial stability is crucial for enhancing the stock's attractiveness.
Positive Factors
Revenue Growth
Sustained ~11.4% revenue growth indicates expanding product adoption and market penetration. Over the next 2–6 months this underlying top-line momentum supports scale benefits, revenue visibility and provides a base to improve operating leverage if management tightens cost controls.
Negative Factors
Negative Profitability
Persistent negative net margins despite revenue growth signal structural cost issues (SG&A, R&D or scale inefficiencies). Without durable operating-cost reduction, the company will struggle to convert sales into sustainable profits and returns, limiting long-term shareholder value creation.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained ~11.4% revenue growth indicates expanding product adoption and market penetration. Over the next 2–6 months this underlying top-line momentum supports scale benefits, revenue visibility and provides a base to improve operating leverage if management tightens cost controls.
Read all positive factors
Suzhou Basecare Medical Corp. Ltd. Class H (2170) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$547.05M
Dividend YieldN/A
Average Volume (3M)121.73K
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue Growth11.43%
EPS Growth4.88%
CountryHK
Employees497
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.41
Shares Outstanding82,713,840
10 Day Avg. Volume98,950
30 Day Avg. Volume121,733
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)0.62
Price to Sales (P/S)2.35
P/FCF Ratio-2.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.23
Revenue Forecast (FY)HK$412.00M
Suzhou Basecare Medical Corp. Ltd. Class H Business Overview & Revenue Model
Company Description
Suzhou Basecare Medical Corporation Limited, an investment holding company, engages in the research, development, manufacture, and provision of genetic testing solutions for assisted reproduction and sale of genetic testing devices and instruments...
How the Company Makes Money
Suzhou Basecare Medical Corp. Ltd. generates revenue through multiple streams, primarily by selling its medical devices and diagnostic products to hospitals, clinics, and healthcare providers. The company benefits from a diversified product portfo...
Suzhou Basecare Medical Corp. Ltd. Class H Financial Statement Overview
Summary
Income Statement
55
Neutral
Balance Sheet
60
Neutral
Cash Flow
50
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 275.71M | 299.11M | 207.98M | 140.90M | 107.30M | 81.11M |
| Gross Profit | 131.54M | 136.22M | 91.35M | 59.53M | 51.15M | 27.71M |
| EBITDA | -226.62M | -253.30M | -174.14M | -117.73M | -118.88M | -873.32M |
| Net Income | -238.59M | -237.03M | -191.69M | -123.16M | -143.65M | -877.05M |
Balance Sheet | ||||||
| Total Assets | 1.57B | 1.67B | 1.90B | 1.78B | 1.80B | 350.30M |
| Cash, Cash Equivalents and Short-Term Investments | 545.48M | 684.63M | 945.71M | 1.33B | 1.52B | 192.32M |
| Total Debt | 342.23M | 328.42M | 281.92M | 75.54M | 48.57M | 31.47M |
| Total Liabilities | 535.35M | 527.47M | 499.98M | 188.33M | 85.85M | 68.96M |
| Stockholders Equity | 1.03B | 1.14B | 1.40B | 1.59B | 1.72B | 281.33M |
Cash Flow | ||||||
| Free Cash Flow | -297.35M | -322.41M | -371.44M | -317.52M | -234.71M | -72.38M |
| Operating Cash Flow | -207.59M | -229.12M | -267.23M | -188.77M | -197.85M | -64.29M |
| Investing Cash Flow | -1.63M | -181.19M | -324.81M | -88.70M | -56.60M | 33.53M |
| Financing Cash Flow | -2.45M | 33.78M | 190.55M | 23.51M | 1.60B | 207.47M |
Suzhou Basecare Medical Corp. Ltd. Class H Technical Analysis
Positive
1.97
Price Trends
1.94
Positive
2.05
Negative
2.54
Negative
Market Momentum
0.01
Negative
52.34
Neutral
63.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2170, the sentiment is Positive. The current price of 1.97 is below the 20-day moving average (MA) of 1.99, above the 50-day MA of 1.94, and below the 200-day MA of 2.54, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 52.34 is Neutral, neither overbought nor oversold. The STOCH value of 63.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2170.
Suzhou Basecare Medical Corp. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | HK$965.82M | -1.91 | -30.05% | ― | -8.56% | -14.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$4.12B | -6.84 | -11.27% | ― | 29.25% | 9.02% | |
44 Neutral | HK$547.05M | -2.91 | -21.93% | ― | 11.43% | 4.88% | |
44 Neutral | HK$3.12B | -495.98 | -1.35% | ― | 49.86% | 80.35% | |
43 Neutral | HK$3.69B | -218.71 | 0.22% | ― | -4.38% | ― | |
41 Neutral | HK$724.37M | -4.03 | -9.19% | ― | -30.60% | 28.61% |
* Healthcare Sector Average
HK:2170
Suzhou Basecare Medical Corp. Ltd. Class H
2.00
-0.85
-29.82%
HK:9996
Peijia Medical Ltd.
6.14
1.66
37.05%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.90
-0.90
-23.68%
HK:2216
Broncus Holding Corp.
1.37
0.54
65.06%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
7.40
1.48
25.00%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
2.19
0.38
20.99%
Suzhou Basecare Medical Corp. Ltd. Class H Corporate Events
Suzhou Basecare Non-Executive Director Ling Yang Resigns
Jan 15, 2026
Suzhou Basecare Medical Corporation Limited has announced the resignation of non-executive director Ling Yang, effective 15 January 2026, citing personal work arrangements. The board confirmed that his departure will not reduce the number of direc...
Suzhou Basecare Medical Sets Out Board and Committee Structure
Jan 15, 2026
Suzhou Basecare Medical Corporation Limited has announced the composition of its board of directors, led by chairman and executive director Dr. Liang Bo, alongside two other executive directors, two non-executive directors and three independent no...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.